midazolam has been researched along with Kidney Failure, Chronic in 11 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam is a short-acting water-soluble benzodiazepine (at pH less than 4), a member of a new class of imidazobenzodiazepine derivatives." | 3.75 | Midazolam. A review of its pharmacological properties and therapeutic use. ( Brogden, RN; Dundee, JW; Halliday, NJ; Harper, KW, 1984) |
| " Anesthesia was maintained with fentanyl and midazolam." | 3.69 | [The anesthetic management of patients in chronic renal failure for coronary artery bypass surgery without cardiopulmonary bypass]. ( Gotou, K; Hashimoto, Y; Kimura, F; Kimura, N; Wakayama, S, 1997) |
| "Fexofenadine clearance was not affected by time after dialysis (P = 0." | 1.56 | Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease. ( Åsberg, A; Christensen, H; Egeland, EJ; Robertsen, I; Witczak, BJ; Zaré, HK, 2020) |
| "ESRD can affect the pharmacokinetic disposition of drugs subject to nonrenal clearance." | 1.35 | ESRD impairs nonrenal clearance of fexofenadine but not midazolam. ( Frye, RF; Himmelfarb, J; Le, P; Leblond, FA; Naud, J; Nolin, TD; Pichette, V; Sadr, H, 2009) |
| "He had chronic renal failure and on hemodialysis (HD) for 22 years." | 1.31 | [General anesthesia for a patient on hemodialysis with arteriosclerosis obliterans]. ( Hanaoka, K; Nishiyama, T; Otsuji, M; Yajima, C, 2000) |
| "Midazolam was administered for premedication (5 mg per os) and for the induction of anaesthesia (2 mg intravenous)." | 1.30 | [Prolonged effect of midazolam with delayed postanesthetic recovery from the possible interference of famotidine]. ( Barrau, P; Bazin, JE; Bérard, JP; Giannelloni, C; Gindre, G, 1998) |
| " The pharmacokinetic parameters in CRF patients were compared with those of healthy volunteers matched for age, sex, and body size with the CRF patients." | 1.27 | The pharmacokinetics of midazolam in chronic renal failure patients. ( Abernethy, DR; Greenblatt, DJ; Reves, JG; Smith, LR; Vinik, HR, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Egeland, EJ | 1 |
| Witczak, BJ | 1 |
| Zaré, HK | 1 |
| Christensen, H | 1 |
| Åsberg, A | 1 |
| Robertsen, I | 1 |
| Rutkowska, K | 1 |
| Knapik, P | 1 |
| Misiolek, H | 1 |
| Nolin, TD | 1 |
| Frye, RF | 1 |
| Le, P | 1 |
| Sadr, H | 1 |
| Naud, J | 1 |
| Leblond, FA | 1 |
| Pichette, V | 1 |
| Himmelfarb, J | 1 |
| Honda, A | 1 |
| Arai, T | 1 |
| Akiyama, M | 1 |
| Masuda, E | 1 |
| Kobayashi, M | 1 |
| Hoka, S | 1 |
| Dundee, JW | 1 |
| Halliday, NJ | 1 |
| Harper, KW | 1 |
| Brogden, RN | 1 |
| Vinik, HR | 1 |
| Reves, JG | 1 |
| Greenblatt, DJ | 1 |
| Abernethy, DR | 1 |
| Smith, LR | 1 |
| Cameron, EM | 1 |
| Lisbon, A | 1 |
| Moorman, R | 1 |
| Young, JD | 1 |
| Kingsley, CP | 1 |
| Chronister, T | 1 |
| Cohen, DJ | 1 |
| Parrish, JM | 1 |
| Drew, R | 1 |
| Bongiovanni, MB | 1 |
| Gotou, K | 1 |
| Kimura, F | 1 |
| Kimura, N | 1 |
| Hashimoto, Y | 1 |
| Wakayama, S | 1 |
| Barrau, P | 1 |
| Giannelloni, C | 1 |
| Gindre, G | 1 |
| Bérard, JP | 1 |
| Bazin, JE | 1 |
| Otsuji, M | 1 |
| Nishiyama, T | 1 |
| Yajima, C | 1 |
| Hanaoka, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparative Study of Sevoflurane Sedation With TCI Propofol Sedation in Dialysis Dependent End Stage Renal Failure Patients for Transposition of Brachiocephalic Fistula Repair[NCT04839536] | Phase 4 | 36 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Comparison Between Music Therapy and Intravenous Midazolam 0,02 mg/kgBW in Reducing Preoperative Anxiety: Study on Patient Undergoing Brachytherapy With Spinal Anesthesia[NCT03269929] | 60 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for midazolam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Midazolam. A review of its pharmacological properties and therapeutic use.
Topics: Benzodiazepines; Clinical Trials as Topic; Drug Interactions; Humans; Hypnotics and Sedatives; Intes | 1984 |
2 trials available for midazolam and Kidney Failure, Chronic
| Article | Year |
|---|---|
The effect of dexmedetomidine sedation on brachial plexus block in patients with end-stage renal disease.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Brachial Plexus; Dexmedetomidine; Female; Humans; Hypnot | 2009 |
Midazolam. A review of its pharmacological properties and therapeutic use.
Topics: Benzodiazepines; Clinical Trials as Topic; Drug Interactions; Humans; Hypnotics and Sedatives; Intes | 1984 |
9 other studies available for midazolam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Drug Interact | 2020 |
ESRD impairs nonrenal clearance of fexofenadine but not midazolam.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Urea Nitrogen; | 2009 |
Anesthetic management of a patient with a history of Batista procedure for dilated cardiomyopathy undergoing gastric surgery.
Topics: Anesthesia, Epidural; Anesthesia, General; Anesthetics, Intravenous; Anesthetics, Local; Bupivacaine | 2006 |
The pharmacokinetics of midazolam in chronic renal failure patients.
Topics: Adult; Benzodiazepines; Female; Half-Life; Humans; Infusions, Parenteral; Kidney Failure, Chronic; K | 1983 |
Prolonged neuromuscular blockade with pipecuronium in a patient with renal insufficiency.
Topics: Aged; Anesthesia, Intravenous; Evoked Potentials; Humans; Kidney Failure, Chronic; Male; Midazolam; | 1994 |
Case 2--1996. Anesthetic management of a patient with hemoglobin SS disease and mitral insufficiency for mitral valve repair.
Topics: Anemia, Sickle Cell; Anesthesia, Intravenous; Anesthetics, Intravenous; Cardiopulmonary Bypass; Eryt | 1996 |
[The anesthetic management of patients in chronic renal failure for coronary artery bypass surgery without cardiopulmonary bypass].
Topics: Adult; Anesthesia; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Disease; Fentanyl; Human | 1997 |
[Prolonged effect of midazolam with delayed postanesthetic recovery from the possible interference of famotidine].
Topics: Accidental Falls; Adjuvants, Anesthesia; Aged; Anesthesia Recovery Period; Anesthesia, General; Drug | 1998 |
[General anesthesia for a patient on hemodialysis with arteriosclerosis obliterans].
Topics: Anesthesia, General; Arteriosclerosis Obliterans; Blood Pressure; Carotid Arteries; Fentanyl; Humans | 2000 |